Committee Composition

Richard L. Anderson, has been the Corporate Vice President and Chief Financial Officer of Mannkind Corporation, a biopharmaceutical company, since October 2002. From January 1997 to September 2002, Mr. Anderson held various executive positions at NeoRx Corporation, a Seattle-based publicly traded biotechnology company, including President, Chief Operating Officer, Chief Financial Officer and Senior Vice President, Finance and Operations. Mr. Anderson holds a master's degree in Management from Johns Hopkins University, a master's degree in solid state physics from the University of Maryland and a bachelor's degree in physics from Bucknell University.

Lawrence K. Cohen, PhD, has served as President, Chief Executive Officer and a director of VIA since VIA's formation in 2004. Previously, he was Chief Executive Officer of Zyomyx, Inc., a proteomics technology company. Dr. Cohen joined Zyomyx in 1999 as Chief Operating Officer, where he was responsible for all internal activities, including research and development, business development, financing and operations. From 1997 to 1998 Dr. Cohen was Chief Operating Officer of Progenitor, Inc., a publicly traded genomics company, and from 1988 to 1997, he was Vice President of REsearch and Development at Somatix Therapy Corporation, a publicly traded gene therapy company. Dr. Cohen received a PhD in Microbiology from the University of Illinois and completed his postdoctoral work in Molecular Biology at the Dana-Farber Cancer Institute and the Department of Biological Chemistry at Harvard Medical School.

Douglass B. Given, MD, PhD, MBA, has served as Chairman of VIA's Board of Directors since the Company's formation in 2004. Dr. Given is a partner at Bay City Capital LLC, which manages investment funds in the life sciences industry, and was founded in June 1997. From July 2001 to June 2003, Dr. Given served as the Chief Executive Officer, Corporate Senior Vice President and Director of NeoRx Corporation, a cancer therapeutics company. Dr. Given was Corporate Senior Vice President and Chief Technology Officer of Mallinckrodt, Inc. from August 1999 to October 2000. Dr. Given serves on advisory boards to the University of Chicago for Biological Sciences, the Pritzker School of Medicine and Johns Hopkins Bloomberg School of Public Health. Dr. Given is Chairman of Vivaldi Biosciences, an anti-viral and vaccine development company. He is a director of several biopharmaceutical companies, including Sembiosys Genetics and Aksys, Ltd. Dr. Given earned his MD and PhD from the University of Chicago and his MBA from the Wharton School, University of Pennsylvania. He was a fellow in Internal Medicine and Infectious Diseases at Harvard Medical School and Massachusetts General Hospital.

John Larson is a founder of Prolifaron, Inc., an early-stage biotechnology company started in 1997 and sold to Alexion Pharmaceuticals, Inc. in 2000, and a founder of Materia, Inc., a research and development company specializing in new applications of patented polymer products. Mr. Larson served as a director for Prolifaron, Inc. from April 1997 to September 2000 and a director of Materia, Inc. from 1997 to 1999. Since December 1999, he has served as the Managing Director of Clique Capital, LLC, a venture capital company focused in the healthcare and technology area. Mr. Larson practiced law for 25 years concentrating in the areas of securities and finance. Mr. Larson has been a frequent speaker on securities matters, having served as Commissioner of Securities and Chairman of the Commerce Commission for the State of Minnesota. In such capacity, Mr. Larson served on a number of committees for the North American Securities Administrators Association, Inc. and the National Association of Securities Dealers, Inc. Mr. Larson holds a B.A. degree from Minnesota State University and a J.D. from William Mitchell College of Law.